The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from October 9, 2024, to July 10, 2025 [3]. - Allegations include that Capricor provided investors with misleading information about deramiocel's Biologics License Application (BLA) and concealed adverse facts regarding its Phase 2 HOPE-2 trial safety and efficacy data [3]. Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 per share to $7.64 per share [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 15, 2025, to monitor the case's progress [4]. - Registration allows shareholders to receive updates and does not incur any costs or obligations [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to false or misleading statements by companies [5].